These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 34200178)

  • 1. PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells.
    Bajbouj K; Ramakrishnan RK; Saber-Ayad M; Omar HA; Saheb Sharif-Askari N; Shafarin J; Elmoselhi AB; Ihmaid A; AlHaj Ali S; Alalool A; Abdullah R; Hamid Q
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin.
    Zhang B; Dong S; Li Z; Lu L; Zhang S; Chen X; Cen X; Wu Y
    J Transl Med; 2015 Nov; 13():349. PubMed ID: 26541651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
    Zhang B; Dong S; Zhu R; Hu C; Hou J; Li Y; Zhao Q; Shao X; Bu Q; Li H; Wu Y; Cen X; Zhao Y
    Oncotarget; 2015 Sep; 6(26):22799-811. PubMed ID: 26078354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arginine methyltransferase inhibitor 1 exhibits antitumor effects against cervical cancer
    Dong SH; Wang X; Tian SC; Ma NQ; Zhang XY; Liu Y; Zhang BL; Wu YJ
    Pharmazie; 2018 May; 73(5):269-273. PubMed ID: 29724292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth.
    Zhang S; Ma Y; Hu X; Zheng Y; Chen X
    J Cell Mol Med; 2019 Feb; 23(2):1333-1342. PubMed ID: 30461193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of PRMT5 by AMI-1 enhances therapeutic efficacy of compound kushen injection in lung carcinoma in vitro and in vivo.
    Yang R; Dong S; Zhang J; Zhu S; Miao G; Zhang B
    Mol Cell Biochem; 2023 May; 478(5):1031-1044. PubMed ID: 36214894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
    Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
    Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arginine methyltransferase inhibitor 1 inhibits gastric cancer by downregulating eIF4E and targeting PRMT5.
    Zhang B; Zhang S; Zhu L; Chen X; Zhao Y; Chao L; Zhou J; Wang X; Zhang X; Ma N
    Toxicol Appl Pharmacol; 2017 Dec; 336():1-7. PubMed ID: 28987382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein arginine methyltransferase 5 is essential for growth of lung cancer cells.
    Gu Z; Gao S; Zhang F; Wang Z; Ma W; Davis RE; Wang Z
    Biochem J; 2012 Sep; 446(2):235-41. PubMed ID: 22708516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling.
    Jing P; Zhao N; Ye M; Zhang Y; Zhang Z; Sun J; Wang Z; Zhang J; Gu Z
    Cancer Lett; 2018 Jul; 427():38-48. PubMed ID: 29679612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition.
    Ibrahim R; Matsubara D; Osman W; Morikawa T; Goto A; Morita S; Ishikawa S; Aburatani H; Takai D; Nakajima J; Fukayama M; Niki T; Murakami Y
    Hum Pathol; 2014 Jul; 45(7):1397-405. PubMed ID: 24775604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance.
    Jensen-Pergakes K; Tatlock J; Maegley KA; McAlpine IJ; McTigue M; Xie T; Dillon CP; Wang Y; Yamazaki S; Spiegel N; Shi M; Nemeth A; Miller N; Hendrickson E; Lam H; Sherrill J; Chung CY; McMillan EA; Bryant SK; Palde P; Braganza J; Brooun A; Deng YL; Goshtasbi V; Kephart SE; Kumpf RA; Liu W; Patman RL; Rui E; Scales S; Tran-Dube M; Wang F; Wythes M; Paul TA
    Mol Cancer Ther; 2022 Jan; 21(1):3-15. PubMed ID: 34737197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRMT5 promotes chemotherapy-induced neuroendocrine differentiation in NSCLC.
    Shen Q; Liu Y; Deng X; Hu CD
    Thorac Cancer; 2023 Jun; 14(18):1764-1773. PubMed ID: 37140020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression.
    Chen H; Lorton B; Gupta V; Shechter D
    Oncogene; 2017 Jan; 36(3):373-386. PubMed ID: 27270440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer.
    Pang J; Ye L; Zhao D; Zhao D; Chen Q
    Cell Biol Int; 2020 Dec; 44(12):2416-2426. PubMed ID: 32808744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An AKT/PRMT5/SREBP1 axis in lung adenocarcinoma regulates de novo lipogenesis and tumor growth.
    Liu L; Yan H; Ruan M; Yang H; Wang L; Lei B; Sun X; Chang C; Huang G; Xie W
    Cancer Sci; 2021 Aug; 112(8):3083-3098. PubMed ID: 34033176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-324-5p upregulation potentiates resistance to cisplatin by targeting FBXO11 signalling in non-small cell lung cancer cells.
    Ba Z; Zhou Y; Yang Z; Xu J; Zhang X
    J Biochem; 2019 Dec; 166(6):517-527. PubMed ID: 31778188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
    Wang Y; Hu W; Yuan Y
    J Med Chem; 2018 Nov; 61(21):9429-9441. PubMed ID: 29870258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
    Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
    J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors.
    Zhu K; Song JL; Tao HR; Cheng ZQ; Jiang CS; Zhang H
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3693-3699. PubMed ID: 30366617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.